# Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

> **NCT01740557** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Metastatic Melanoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** NGFR-transduced Autologous T Lymphocytes
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT01740557
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-28
- **Primary completion:** 2023-04-21
- **Final completion:** 2023-04-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740557, "Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01740557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*